Amgen Inc (AMGN)
Mexican Exchange · Mexico · prices in MXN · close of 22 Oct 2026
Key indicators
| Last close | MXN 8,390.00 |
|---|---|
| 52-week range | 5,300.00 – 8,390.00 |
| Return, 1 month / 3 months | +23.9% / +32.7% |
| Return, 1 year / 3 years | +56.8% / +95.3% |
| Trend | Uptrend |
| RSI (14) | 88 |
| Volatility (1 year) | 34.4% |
| Worst drawdown (1 year) | -15.8% |
| Average daily value traded | 0.33M MXN |
| Dividend yield | 2.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Amgen is a biotechnology company that discovers, develops and makes medicines for serious illnesses. Its products include treatments for inflammatory conditions, cancer support, bone loss, kidney disease and high cholesterol, sold mainly to hospitals, clinics and healthcare providers. The company is based in Thousand Oaks, California, and serves patients and medical markets around the world through its own sales teams and partnerships.
Amgen Inc trades under the code AMGN on the Mexican Exchange in Mexico, with its price quoted in Mexican pesos (MXN). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Amgen Inc (AMGN) trades on the Mexican Exchange in Mexico. It last closed at MXN 8,390.00 on 22 October 2026.
Its price-based Market X-Ray is 69 out of 100 (a fair price profile), ranking 33 of 361 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 56.8% and over the last three months it rose 32.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Mexican Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 91 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 31.0% | ||
| From 52-week high | 0.0% | ||
| Momentum | 88 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 32.7% | ||
| 6-month return | 38.3% | ||
| 12-month return, skipping the last month | 26.6% | ||
| Stability (higher is calmer) | 55 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 34.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -15.8% | ||
| Liquidity | 29 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.33M MXN | ||
| Zero-volume days | 75.0% | ||
| Income | 62 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.1% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +11.9% |
|---|---|
| 1 month | +23.9% |
| 3 months | +32.7% |
| 6 months | +38.3% |
| 1 year | +56.8% |
| 3 years | +95.3% |
| 5 years | +130.8% |
Signals
| 50-day / 200-day average | 7,250.45 / 6,402.98 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 103.04 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 21 Aug 2026 | MXN 42.6208 |
| 15 May 2026 | MXN 43.7233 |
| 13 Feb 2026 | MXN 43.3087 |
| 21 Nov 2025 | MXN 44.0443 |
| 22 Aug 2025 | MXN 44.2442 |
| 16 May 2025 | MXN 46.5361 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Mexican Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.